Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials

Christopher B Cooper 1
Antonio Anzueto 2
Marc Decramer 3
Bartolome Celli 4
Donald P Tashkin 1
Inge Leimer 5
Steven Kesten 6

1 David Geffen School of Medicine, University of California, Los Angeles, CA; 2 University of Texas Health Science Center, South Texas Veterans Health Care System, San Antonio, TX; 3 University of Leuven, Leuven, Belgium; 4 Women’s and Brigham Hospital, Boston, MA; 5 Boehringer Ingelheim International Gmbh, Ingelheim, Germany; 6 Uptake Medical Corp, Tustin, CA, USA

Background: Data have highlighted the potential bias introduced by withdrawal of inhaled corticosteroids at randomization in chronic obstructive pulmonary disease trials examining inhaled corticosteroids. Analyses were conducted to determine whether this was true of inhaled anticholinergic withdrawal in tiotropium trials.

Methods: A pooled analysis of randomized, double-blind, placebo-controlled, parallel-group tiotropium trials of at least six months’ duration was performed. Trials had similar inclusion and exclusion criteria. Patients were divided into two groups, ie, D (anticholinergics discontinued at randomization, previously prescribed) and ND (anticholinergics not discontinued, not previously prescribed).

Results: Demographics were balanced between the D (n = 5846) and ND (n = 6317) groups, except for higher cumulative smoking (56 pack-years versus 48 pack-years), lower forced expiratory volume in one second (FEV1)/forced vital capacity (43% versus 48%), and lower baseline FEV1 (35.8% predicted versus 42.4% predicted) in the D group. In both groups, tiotropium reduced the risk for an exacerbation (hazard ratio [HR] = 0.83, P = 0.0001 [D] versus 0.79, P = 0.0001 [ND]) and a hospitalized exacerbation (HR = 0.85, P = 0.0467 versus 0.79, P = 0.0094). Tiotropium reduced the number of exacerbations per patient-year (rate ratio [RR] = 0.82, P = 0.0001 [D] versus RR = 0.80, P = 0.0001 [ND]) and associated hospitalizations per patient-year (RR = 0.88, P = 0.015 [D] versus RR = 0.74, P < 0.0001 [ND]).

Conclusion: Tiotropium reduced exacerbations in patients who did and did not have anticholinergics discontinued upon randomization in clinical trials.

Keywords: chronic obstructive pulmonary disease, clinical trials, exacerbations, inhaled anticholinergics, tiotropium

Introduction

The randomized, controlled clinical trial is an attempt to minimize bias introduced by the knowledge of treatment allocation and, thereby, come to reliable conclusions regarding the hypothesis tested. Many interventional, randomized, controlled clinical trials need to assume that randomization distributes baseline characteristics equally, and that patients enter the clinical trial in a stable state. However, inclusion and exclusion criteria can lead to biases which are not necessarily anticipated. When the intervention examined is already used by any portion of the population, patients need to be withdrawn from the intervention. While this may be drug-specific, the withdrawal of previously prescribed medication is often based on the pharmacologic
class or mechanism of action of the study drug. Most trials assume that patients are medically stable at randomization, but withdrawal of medication may worsen the underlying disease.

Three groups of investigators1–3 have highlighted issues introduced by withdrawal of inhaled corticosteroids at randomization into clinical trials examining inhaled corticosteroids in chronic obstructive pulmonary disease (COPD). Suissa et al4 concluded that the effects of withdrawal of medication cannot be assumed to be the same as addition of the medication. While the authors demonstrated this to be the case with inhaled corticosteroids, they considered whether withdrawal of other COPD medication, including inhaled anticholinergics, may lead to a similar phenomenon.

Our access to the tiotropium clinical trial database allowed us to undertake a thorough analysis of whether withdrawal of inhaled anticholinergics influenced the results observed with tiotropium on reducing COPD exacerbations. To our knowledge, this is the first analysis that has examined the issue of medication withdrawal at the onset of clinical trials of anticholinergic therapy.

Methods

Study design

A pooled analysis of 10 randomized, double-blind, placebo-controlled, parallel-group studies of at least six months’ duration with tiotropium 18 µg administered once daily via the HandiHaler® device (Boehringer Ingelheim GmbH, Ingelheim, Germany) was performed (trial numbers 205.114/117, 205.115/128, 205.130, 205.137, 205.266, 205.270, 205.235) [Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT®), 205.214, 205.256, 205.259], as shown in Figure 1. One study was longer than one year (UPLIFT, which included 5993 COPD patients followed over four years).5 All trials included measurement of exacerbations and spirometry. Seven trials (trial numbers 205.114/117, 205.115/128, 205.130, 205.137, 205.235 [UPLIFT], 205.256, and 205.259) included measurement using the St George’s Respiratory Questionnaire (SGRQ).13 All trial protocols were approved by independent ethics committees, and patients in all trials provided written informed consent. The trials were conducted in accordance with the Declaration of Helsinki.

Study population

All trials included in this pooled analysis had common entry criteria, ie, a clinical diagnosis of COPD, age ≥40 years, smoking history ≥10 pack-years, postbronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity ratio <0.7, and FEV1 either ≤65% or ≥70% of predicted. Whilst the patients participating in these studies were classified as to the severity of their COPD on the basis of post-bronchodilator FEV1 measurements, the data reported in this paper were prebronchodilator values.

Exclusion criteria included a history of asthma, the need for continuous supplemental oxygen, a COPD exacerbation within the previous six weeks, recent myocardial infarction or hospitalization for congestive heart failure, other unstable medical conditions that may preclude participation or interpretation of the results, and use of systemic corticosteroids in doses greater than the equivalent of prednisone 10 mg daily. Responsiveness to bronchodilator therapy was not measured consistently between the clinical trials. Therefore, these measurements were not included in the data analysis. Consistent clinical criteria were applied to exclude patients with asthma. We believe that this is the most dependable method for excluding patients with asthma, given that it is now well known that bronchodilator responsiveness does not discriminate between asthma and COPD.

COPD exacerbations

All trials included data on COPD exacerbations. The following standardized definition was used to characterize COPD exacerbations in the current analysis: “An exacerbation is defined by two or more (increased or new-onset)
respiratory symptoms such as cough, sputum, wheezing, dyspnea, or chest tightness, lasting at least three days, and requiring treatment with antibiotics and/or steroids, and/or hospitalization. 

Patients were grouped according to inhaled anticholinergic discontinuation, ie, D (anticholinergic prescribed prior to participation and discontinued at randomization) and ND (anticholinergic not prescribed prior to participation and therefore not discontinued).

Data analysis
Kaplan–Meier curves of the probability of no exacerbation and no hospitalization due to exacerbations were displayed. Cox regression was used to compute hazard ratios (HR) of tiotropium to placebo using trial as stratum.

The analysis of number of exacerbations and number of hospitalizations due to exacerbations was performed using Poisson regression, with correction for treatment exposure and overdispersion with terms for treatment subgroup and treatment by subgroup interaction. The effects of tiotropium or placebo on the SGRQ total score in trials where the SGRQ was measured was examined according to whether or not subjects discontinued anticholinergic therapy. These data are displayed as mean (standard error of the mean) values and have been compared with unpaired t-tests.

Results
Demographics
Of the 12,163 patients who were randomized into these clinical trials, 5846 were receiving inhaled anticholinergics that were discontinued at randomization (D group) and 6317 were not receiving inhaled anticholinergics at the time of randomization (ND group). The inhaled anticholinergic was ipratropium bromide in the vast majority of patients who were already receiving inhaled anticholinergics. At time of initiation of all of the aforementioned trials, tiotropium was not available in the respective countries where the studies were performed. Approval of tiotropium occurred in several of the trials during the recruitment phase. There were a few patients who did receive tiotropium prior to randomization (109 of 12,164 patients), with 49 being withdrawn from tiotropium. The baseline characteristics of these patients are shown in Table 1. For group D, the mean age was 66.1 years compared with 64.5 years for the ND group. Gender distribution was similar across groups. Patients who had previously been prescribed anticholinergics had lower

Table 1 Baseline characteristics* of patients according to treatment allocation (tiotropium or placebo)

<table>
<thead>
<tr>
<th></th>
<th>Discontinued</th>
<th></th>
<th>Not discontinued</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>Tiotropium</td>
<td>Placebo</td>
<td>Tiotropium</td>
</tr>
<tr>
<td>Number of patients (%)</td>
<td>2783 (100.0)</td>
<td>3063 (100.0)</td>
<td>3085 (100.0)</td>
<td>3232 (100.0)</td>
</tr>
<tr>
<td>Age, years</td>
<td>66.1 (8.6)</td>
<td>66.1 (8.4)</td>
<td>64.6 (9.0)</td>
<td>64.4 (8.8)</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>577 (20.7)</td>
<td>623 (20.3)</td>
<td>712 (23.1)</td>
<td>762 (23.6)</td>
</tr>
<tr>
<td>Male</td>
<td>2206 (79.3)</td>
<td>2440 (79.7)</td>
<td>2373 (76.9)</td>
<td>2470 (76.4)</td>
</tr>
<tr>
<td>Smoking history, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exsmoker</td>
<td>1972 (70.9)</td>
<td>2176 (71.0)</td>
<td>2084 (67.6)</td>
<td>2193 (67.9)</td>
</tr>
<tr>
<td>Never smoked</td>
<td>1 (0.0)</td>
<td>0 (0.0)</td>
<td>1 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Smoker</td>
<td>809 (29.1)</td>
<td>887 (29.0)</td>
<td>1000 (32.4)</td>
<td>1038 (32.1)</td>
</tr>
<tr>
<td>Missing</td>
<td>1 (0.0)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>1 (0.0)</td>
</tr>
<tr>
<td>Smoking history, pack-years</td>
<td>55.6 (32.3)</td>
<td>55.5 (30.9)</td>
<td>47.6 (27.5)</td>
<td>48.8 (26.7)</td>
</tr>
<tr>
<td>BMI</td>
<td>26.3 (5.5)</td>
<td>26.4 (5.5)</td>
<td>26.2 (5.3)</td>
<td>26.3 (5.3)</td>
</tr>
<tr>
<td>FEV1, % predicted†</td>
<td>36.0 (12.4)</td>
<td>35.7 (12.3)</td>
<td>42.0 (12.6)</td>
<td>42.7 (12.8)</td>
</tr>
<tr>
<td>FEV1/FVC†</td>
<td>0.43 (0.11)</td>
<td>0.43 (0.11)</td>
<td>0.47 (0.12)</td>
<td>0.48 (0.12)</td>
</tr>
<tr>
<td>GOLD stage, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>1 (0.0)</td>
<td>0 (0.0)</td>
<td>1 (0.0)</td>
<td>7 (0.2)</td>
</tr>
<tr>
<td>II</td>
<td>436 (15.7)</td>
<td>444 (14.5)</td>
<td>873 (28.3)</td>
<td>964 (29.8)</td>
</tr>
<tr>
<td>III</td>
<td>1351 (48.5)</td>
<td>1509 (49.3)</td>
<td>1614 (52.3)</td>
<td>1662 (51.4)</td>
</tr>
<tr>
<td>IV</td>
<td>966 (34.7)</td>
<td>1077 (35.2)</td>
<td>554 (18.0)</td>
<td>548 (17.0)</td>
</tr>
<tr>
<td>Missing</td>
<td>29 (1.0)</td>
<td>33 (1.1)</td>
<td>43 (1.4)</td>
<td>51 (1.6)</td>
</tr>
<tr>
<td>Receiving systemic corticosteroids, n (%)</td>
<td>295 (10.6)</td>
<td>283 (9.2)</td>
<td>137 (4.4)</td>
<td>145 (4.5)</td>
</tr>
</tbody>
</table>

Notes: *Mean (SD) unless otherwise specified. No BMI data available for study 205.214 because weights were not collected. †prebronchodilator values. GOLD based on prebronchodilator values: Stage I = mild (FEV1 ≥ 80% predicted); Stage II = moderate (FEV1 = 50% to <80% predicted); Stage III = severe (FEV1 < 50% to ≥30% predicted); Stage IV = very severe (FEV1 < 30% predicted). “Not discontinued” means either “not discontinued from anticholinergics” or “never took anticholinergics”.

Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SD, standard deviation.
lung function and longer smoking histories. Overall, within the D and ND groups, the treatment subgroups (tiotropium and placebo) were reasonably well balanced with respect to their baseline characteristics.

Exacerbations
There was a significantly reduced risk of an exacerbation in patients receiving tiotropium compared with those receiving placebo in the D group (HR [95% confidence interval (CI)] = 0.83 [0.77–0.90]) and in the ND groups (HR [95% CI] = 0.79 [0.73–0.85]). Similar findings were observed for exacerbations leading to hospitalizations with an HR (95% CI) of 0.85 (0.73–1.00) in the D group and 0.79 (0.65–0.94) in the ND group. Tiotropium delayed the time to first exacerbation and first hospitalized exacerbation in both the D and ND groups, as observed in the cumulative incidence displays (Figures 2 and 3).

The number of patients having at least one exacerbation and at least one exacerbation leading to hospitalization was reduced with tiotropium relative to placebo in both D and ND groups, as reflected by lower rate ratios (Tables 2 and 3). Furthermore, these effects were similar for patients in both D and ND groups.

St. George’s respiratory questionnaire
For the D group, the mean (standard error) total SGRQ score at six months was improved with tiotropium (41.4 [0.31]) relative to those receiving placebo (44.7 [0.34], difference = 3.33 [0.40], P < 0.0001). For the ND group, the total scores were also improved with tiotropium versus placebo (40.3 compared with 43.1, difference = 2.78, P < 0.0001).

Discussion
The pooled analysis of 10 randomized, double-blind, placebo-controlled clinical trials involving 12,163 patients with COPD demonstrates that tiotropium was effective in reducing exacerbations in patients who did and also those who did not have inhaled anticholinergics discontinued upon...
randomization. In patients who discontinued anticholinergic therapy, there was a 17% risk reduction for an exacerbation when treated with tiotropium compared with placebo. In patients who did not discontinue anticholinergic therapy, the risk reduction was 21% with tiotropium compared with placebo. In a similar comparison, the risk for a hospitalized exacerbation was reduced by 15% and 21%, respectively.

The reduced risk was also associated with reduced rates of exacerbations and hospitalized exacerbations, regardless of previous anticholinergic use. Thus, withdrawal of inhaled anticholinergics upon entry into tiotropium trials did not appear to influence the effect of tiotropium on the clinically important patient outcome of exacerbations of COPD. In addition, in the seven trials where the SGRQ was measured, tiotropium significantly reduced the SGRQ total score in both groups of patients.

Exacerbations are a significant component of the clinical course in COPD. Furthermore, as COPD progresses, exacerbations become more frequent. Some investigators have suggested that more frequent exacerbations are associated with more rapid decline of FEV1. Certainly, exacerbations have profound effects on quality of life. For example, SGRQ scores have been shown to be decreased below baseline for up to six months following an exacerbation. Finally, exacerbations are associated with significant mortality. More widespread clinical use of tiotropium in COPD patients might predictably ameliorate the effects of recurrent exacerbations on the clinical course of the disease and impact the design of future clinical trials.

Recently, there have been increasing concerns about the effects of withdrawal of medications on the entry into clinical trials. van der Valk et al treated patients with inhaled fluticasone 1000 µg/day for four months and then randomized the patients to continue receiving fluticasone or to switch to placebo. During the subsequent six months of follow-up, 47% of patients in the fluticasone group developed a COPD exacerbation compared with 57% in the placebo group. Significant differences were seen in the HR for first exacerbation, as well as differences in health-related quality of life as measured by the SGRQ, which favored those patients continuing on fluticasone. However, the question arises as to whether this is a safety concern due to sudden withdrawal of a high dose of systemically absorbed inhaled corticosteroids or if the observations are surrogate measures of efficacy.

Suissa et al described methodological issues in therapeutic trials of COPD, and drew attention to the problem of medication withdrawal using inhaled corticosteroids prior to randomization as an example. In the case of the Canadian Optimal Therapy of COPD Trial (TORCH) study, this phenomenon led in effect to two comparisons, ie, withdrawal of inhaled corticosteroids compared with continuation of inhaled corticosteroids in patients previously taking these agents, and introduction of inhaled corticosteroids compared with placebo in patients not previously taking inhaled corticosteroids. Suissa et al also analyzed data from the Canadian Optimal Therapy of COPD Trial (TORCH) study, and found that the HR (inhaled corticosteroids relative to bronchodilators

### Table 2 Number of patients with at least one exacerbation by discontinuation of anticholinergics

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 5868)</th>
<th>Tiotropium (n = 6295)</th>
<th>Odds ratio (95% confidence interval)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discontinued</td>
<td>1187 (42.7)</td>
<td>1221 (39.9)</td>
<td>0.88 (0.80–0.93)</td>
<td>0.0223</td>
</tr>
<tr>
<td>Not discontinued</td>
<td>1294 (41.9)</td>
<td>1154 (35.7)</td>
<td>0.77 (0.69–0.85)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

**Notes:** Results are based on a logistic regression model with terms for treatment, subgroup, trial and treatment x subgroup interaction. The denominator for the percentages is the number of patients in each combination of subgroup and treatment: discontinued, n (placebo) = 2783, n (tiotropium) = 3063; not discontinued n (placebo) = 3085, n (tiotropium) = 3232.

### Table 3 Number of patients with at least one hospitalization by discontinuation of anticholinergics

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 5868)</th>
<th>Tiotropium (n = 6295)</th>
<th>Odds ratio (95% confidence interval)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discontinued</td>
<td>315 (11.3)</td>
<td>320 (10.4)</td>
<td>0.92 (0.78–1.09)</td>
<td>0.3173</td>
</tr>
<tr>
<td>Not discontinued</td>
<td>255 (8.3)</td>
<td>215 (6.7)</td>
<td>0.79 (0.66–0.96)</td>
<td>0.0160</td>
</tr>
</tbody>
</table>

**Notes:** Results are based on a logistic regression model with terms for treatment, subgroup, trial and treatment x subgroup interaction. The denominator for the percentages is the number of patients in each combination of subgroup and treatment: discontinued: n (placebo) = 2783, n (tiotropium) = 3063; not discontinued: n (placebo) = 3085, n (tiotropium) = 3232.
only) for the first exacerbation among previous inhaled corticosteroids users was 0.71 (95% CI 0.53–0.96), while among those not using inhaled corticosteroids prior to randomization, the HR (inhaled corticosteroids relative to bronchodilators only) was 1.11 (95% CI 0.69–1.79). In addition, the ratio for exacerbations in patients prior to discontinuing inhaled corticosteroids was 0.78 (95% CI 0.61–0.99) compared with 1.23 (95% CI 0.78–1.95) thereafter. These concerns prompted a detailed retrospective analysis of data from TORCH.23 In this paper, Keene et al argued that a negative binomial model was the best approach to statistical analysis of exacerbation rates and that a similar reduction in exacerbations could be calculated regardless of whether or not subjects had discontinued inhaled corticosteroids at randomization.

Suissa et al1 suggested in their paper that withdrawal of inhaled anticholinergic therapy might cause similar problems to those they described related to withdrawal of inhaled corticosteroids. However, our results clearly refute that suggestion. Furthermore, we have demonstrated a similar reduction in the number of exacerbations per patient year in those who continued and those who discontinued inhaled anticholinergic therapy upon randomization into these tiotropium clinical trials. This significant benefit argues that the clinical trial results, in terms of the difference between tiotropium and placebo, favor a positive effect from tiotropium rather than a negative effect from inhaled anticholinergic withdrawal in the placebo group.

As well as demonstrating that tiotropium reduced exacerbations regardless of changes in prior therapy, we were also able to demonstrate that tiotropium, when compared with placebo, improved health-related quality of life (as measured by SGRQ), regardless of whether or not patients had been taking inhaled anticholinergic therapy prior to randomization. The improvement in SGRQ was statistically significant for both the D and ND groups, although numerically greater for those patients who discontinued previous anticholinergic therapy. Such improvements are a predictable complement to the effect on exacerbations.

We can speculate why withdrawal of inhaled anticholinergic therapy does not affect the outcome of placebo-controlled clinical trials of tiotropium, whereas withdrawal of inhaled corticosteroids seems to be problematic. The effect of ipratropium, which is the short-acting anticholinergic taken by many patients prior to entry into the tiotropium trials, is well understood to be restricted to antimuscarinic smooth muscle relaxation and presumably wears off relatively quickly, although there is some evidence that the effects of extended therapy with ipratropium persist longer than the conventional 6–8-hour duration of acute bronchodilation.24 Although considered a short-acting bronchodilator, ipratropium alone or in combination with albuterol has been shown to reduce exacerbations compared with albuterol alone.25 This observation suggests that one should consider whether a “rebound” effect (ie, an increase in exacerbation rate) might be a consequence of ipratropium withdrawal. In a study of nine subjects with mild asthma, Newcomb et al26 described a short-term increase in airway hyperresponsiveness to methacholine upon withdrawal of regular use of ipratropium, which could represent upregulation of muscarinic receptors on the surface of airway smooth muscle cells. However, these findings have not been replicated, and the current analysis demonstrates that a rebound worsening of COPD is unlikely to occur upon withdrawal of ipratropium. The corollary is not necessarily true for inhaled corticosteroids, because there are systemic effects of inhaled corticosteroids and both beneficial effects and adverse events are likely to occur over longer periods of time, which may also delay the onset of safety issues.

As with any meta-analysis, our study has certain limitations.27 We acknowledge that this is a retrospective analysis and includes trials of different size and duration. However, the strengths of the study are the prospective nature of the clinical trials selected for the pooled analysis and the consistency of their entry criteria. Furthermore, these studies were rigorously conducted, randomized, double-blind, controlled clinical trials that provided large numbers of patients, all of whom were included in the analysis.

**Conclusion**

In summary, we have demonstrated that tiotropium reduced exacerbations and hospitalizations in a large number of COPD patients, regardless of whether or not they discontinued inhaled anticholinergic therapy prior to randomization into the placebo-controlled clinical trials. These findings strengthen the validity of conclusions previously reported from these clinical trials that treatment with tiotropium reduces exacerbations, and that the beneficial effect is equally observed whether or not patients had previously received inhaled anticholinergic therapy.

**Acknowledgment**

We wish to acknowledge the support of Dacheng Liu (Boehringer Ingelheim) for the statistical analysis.
Disclosure

Preparation of this paper was funded jointly by Boehringer Ingelheim and Pfizer. The study design, collection, analysis, and interpretation of data were funded by Boehringer Ingelheim and Pfizer.

References